Cycurion receives Nasdaq delisting notice, files appeal to stay trading

Cycurion, Inc. (NASDAQ: CYCU), a cybersecurity solutions company based in McLean, Virginia, received a delisting determination letter from the Nasdaq Stock Market on July 10, 2026, for failing to meet the exchange's minimum bid price requirement.

According to the letter, Cycurion's common stock closed below the $1.00 per share minimum for 31 consecutive business days between May 26, 2026 and July 9, 2026, violating Nasdaq Listing Rule 5550(a)(1). Because the company completed a 1-for-30 reverse stock split on October 27, 2025, Nasdaq determined it is not eligible for the standard 180-day compliance period under Listing Rule 5810(c)(3)(A)(iv), which excludes issuers that have conducted a reverse stock split within the prior one-year period.

Without a hearing request, trading in Cycurion's securities was set to be suspended at the opening of business on July 21, 2026. The company said it plans to request a hearing before the Nasdaq Hearings Panel ahead of the July 17, 2026 deadline. A timely request will stay the suspension pending the panel's decision, allowing shares to continue trading during the appeal process.

Hearings are typically scheduled 30 to 45 days after a request is filed. The company acknowledged there is no assurance the panel will grant continued listing or that compliance will ultimately be restored.

Cycurion's board said it has decided against pursuing another reverse stock split at this time and is evaluating other options for regaining compliance.

Chairman and Chief Executive Officer Kevin Kelly said the company is "continuing to develop a comprehensive, data-driven record of trading activity, supported by internal analysis and external market data."

The company reported an annual revenue run rate exceeding $28 million, citing contracted backlog and recently secured multi-year agreements. The press release states the delisting matter does not affect Cycurion's operations.

You May Also Be Interested In

• Boeing names Ryan Shedd as new SVP and controller
• Silexion Therapeutics faces Nasdaq delisting over equity shortfall
• enVVeno Medical (NVNO) files $100M mixed shelf